Bringing hope and life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Our Phase 3 PolarisDMD clinical trial with edasalonexent in muscular dystrophy has been initiated.
April 1, 2019: Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference
March 14, 2019: Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress
March 13, 2019: Catabasis Pharmaceuticals to Present at Oppenheimer’s 29th Annual Healthcare Conference
We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination.
A potential foundational therapy aimed at improving the lives of all affected by Duchenne.
Join Our Team